Core Viewpoint - The document outlines the management system for subsidiaries of Zhejiang Zhenyuan Co., Ltd., emphasizing the need for orderly, standardized, and efficient operations while controlling investment risks and protecting the rights of the company and its investors [1]. Group 1: General Principles - The management of subsidiaries follows principles of strategic unity and collaborative development, ensuring that subsidiary strategies align with the overall company strategy [2]. - Subsidiaries maintain independent daily operations, allowing them to establish their internal management structures while ensuring compliance with regulatory requirements [2]. - Major transactions or matters that could significantly impact the company or subsidiaries require decision-making and approval from the company [2]. Group 2: Corporate Governance - Subsidiaries must establish governance structures and internal management systems in accordance with relevant laws and regulations [3]. - Subsidiaries are required to hold shareholder meetings and board meetings as per legal requirements, with specific timelines for annual meetings [4]. - Major transactions must be reviewed and approved by the subsidiary's board or shareholders, especially those involving significant investments or contracts [4][5]. Group 3: Personnel and Assessment Management - The company appoints or recommends directors, supervisors, and senior management for subsidiaries, ensuring compliance with subsidiary charters [6]. - A performance assessment mechanism is established for subsidiaries, linking responsibilities and rewards to the performance of subsidiary leaders [7]. - Any failure by subsidiary management to fulfill their responsibilities may lead to disciplinary actions and potential legal liabilities [7]. Group 4: Financial Management - Subsidiaries must adhere to a unified accounting system and establish financial management practices in line with company policies [8]. - The company’s financial management department oversees subsidiary financial activities, including budget preparation and financial reporting [8]. - Subsidiaries are prohibited from applying for bank credit without company approval, ensuring centralized financial control [8][9]. Group 5: Business Control - The company guides subsidiaries in formulating annual business plans and budgets, which must be approved by the company [9]. - Subsidiaries are not allowed to provide external guarantees or donations without prior approval from the company [9][10]. - Any significant transactions outside the approved scope may result in penalties for responsible parties [10]. Group 6: Audit Supervision - The company conducts regular audits of subsidiaries to ensure compliance with laws and internal regulations [11]. - Audits cover various aspects, including legal compliance, management practices, and financial performance [11]. - Subsidiaries must cooperate with audits and provide necessary documentation [11]. Group 7: Information Reporting and Disclosure Management - Subsidiaries must comply with information disclosure regulations and maintain confidentiality of undisclosed information [12]. - Designated personnel are responsible for communication between the company and subsidiaries regarding information management [12]. - Accurate and complete reporting of information is mandatory, with strict penalties for any misrepresentation [12][13]. Group 8: Supplementary Provisions - The company’s relevant departments are tasked with refining management details and processes based on the established system [13]. - Any matters not covered by the system will be governed by applicable laws and company regulations [13]. - The board of directors is responsible for interpreting and amending the management system [13].

Core Viewpoint - The proposed equity transfer of 5.05% stake in Ruikang Pharmaceutical by controlling shareholder Zhang Renhua to Yanquan No. 8 private equity fund has been terminated after nine months due to "significant changes in the objective environment," despite an initial transaction value of 162 million yuan [1][2]. Group 1: Transaction Details - The transaction was initially valued at 162 million yuan, with an unusually lenient payment structure: only 5 million yuan (3.1%) was required as the first payment, followed by 50 million yuan within 15 working days after the transfer, and the remaining 106.9 million yuan allowed to be deferred for 90 days [2]. - The Yanquan Wealth management scale was less than 500 million yuan, with all seven operating funds marked as having a "surviving scale of less than 10 million yuan," indicating a significant funding gap for the transaction [3]. Group 2: Obstacles to Completion - Three main obstacles were identified that typically lead to the failure of such agreements: fundraising difficulties, potential undisclosed issues with the equity, and speculative market behavior [4]. - The mismatch between the capital strength of Yanquan Fund and the scale of the transaction was a substantial barrier to completion [4]. Group 3: Market Context - The termination of this agreement is part of a broader trend, with over ten A-share companies announcing similar terminations in May 2025 alone, surpassing the total from the previous four months and accounting for 25% of such cases in 2023 [5]. - The ongoing weak market environment has made it increasingly difficult for buyers to raise funds, particularly for large equity transfers of companies trading below net asset value [5]. Group 4: Shareholder Dynamics - The background of this transfer reflects the difficulties faced by controlling shareholders, as Ruikang Pharmaceutical's stock price has been persistently below net asset value since 2023, limiting their ability to reduce holdings in the secondary market [6]. - The failed transaction was initially seen as a potential solution to the shareholder's predicament, but the design flaws in the transaction ultimately led to its collapse [6].

Group 1 - The company plans to purchase directors, supervisors, and senior management liability insurance to enhance its risk management system and protect the rights of its executives and investors [1][2] - The insurance coverage limit is set at a maximum of RMB 100 million, with an annual premium not exceeding RMB 800,000 [1] - The insurance period is for 12 months, with the possibility of renewal or reinsurance [1] Group 2 - The decision to purchase the liability insurance was reviewed and approved in the company's board and supervisory meetings held on June 4, 2025 [2] - All directors and supervisors abstained from voting on the proposal, which was then submitted directly to the shareholders' meeting for approval [2] Group 3 - The company intends to cancel its supervisory board and amend its articles of association to improve governance and operational standards [4][5] - The supervisory board's powers will be transferred to the board's audit committee, and relevant internal regulations will be revised accordingly [6]

Group 1 - The company held its 20th meeting of the 10th Board of Directors on June 4, 2025, with all 7 directors present, complying with legal and procedural requirements [2][3] - The Board approved the proposal to cancel the Supervisory Board and amend the Articles of Association, transferring the Supervisory Board's powers to the Audit Committee [3][6] - The Board also approved amendments to the Shareholders' Meeting Rules, changing "Shareholders' General Meeting" to "Shareholders' Meeting" [6][8] Group 2 - The company plans to hold the 2024 Annual Shareholders' Meeting on June 26, 2025, using a combination of on-site and online voting [30][48] - The voting will take place on the same day, with specific time slots for both on-site and online participants [49][50] - Shareholders must register to attend the meeting, with details provided for both in-person and remote registration [60][61] Group 3 - The company nominated candidates for the 11th Board of Directors, including Zhu Weidong, Yin Shiwei, and Gu Congfeng, pending shareholder approval [22][25] - Independent director candidates include Li Wen, Guo Dan, and Li Wenming, also subject to shareholder approval [25][36] - The company will purchase Directors and Officers liability insurance, with the proposal requiring shareholder approval due to the conflict of interest for all directors [28][43]

医药生物周报（25 年第 22 周） 优于大市 血液净化器械行业分析，关注产业链国产替代趋势 证券研究报告 | 2025年06月04日 本周医药板块表现强于整体市场，化学制药板块领涨。本周全部 A 股下跌 0.05%（总市值加权平均），沪深 300 下跌 1.08%，中小板指下跌 1.55%， 创业板指下跌 1.40%，生物医药板块整体上涨 2.21%，生物医药板块表 现强于整体市场。分子板块来看，化学制药上涨 3.83%，生物制品上涨 3.14%，医疗服务上涨 2.46%，医疗器械上涨 0.54%，医药商业下跌 0.39%，中药上涨 0.62%。医药生物市盈率（TTM）34.03x，处于近 5 年历史估值的 69.61%分位数。 血液净化行业受益于人口老龄化与治疗渗透率提升。血液净化的基础治疗 方式包括血液透析/滤过/灌流、腹膜透析、连续性肾脏替代治疗、血浆 置换/吸附等。其中，血液透析是终末期肾病（ESRD）最主要的治疗方 式，全球 ESRD 患者数量持续增长，叠加中国透析治疗率远低于日美等 发达国家，政策推动下透析治疗渗透率提升空间巨大。连续性肾脏替代 治疗（CRRT）是急性肾衰竭等各种危重病救治重要的 ...

2025 年 06 月 04 日 策 略 研 究 医疗与消费周报——药物警戒行业：AI"东风" 正盛，国内工作水平稳健提升 投资要点： 近期观点 1、医药指数本周关注的 6 个子行业多数录得正收益，表现良好。 策 略 定 期 报 告 2、国际医药科学组织理事会（CIOMS）牵头制定的《药物警戒（PV） 领域人工智能（AI）最佳实践框架》草案于 5 月 1 日发布，旨在指导 AI 在药品不良反应监测中的开发与应用。AI 技术有望为药物安全监测 带来革命性改进，但 CIOMS 指出需建立"以风险为导向"的监管和治 理体系。根据临研产业研究院《中国药物警戒产业研究报告》，中国 药物警戒市场增势明显，2023 年全国药品不良反应报告数达 241.9 万 份，监测工作水平不断提升。国内 AI 医疗大模型发展迅速，药物警戒 产业增势强劲，但也需及时制定监管和治理体系。 团队成员 分析师： 赵月(S0210524050016) zy30563@hfzq.com.cn 相关报告 1、突破、主升形态为主——2025.06.03 2、 5 月 新 股 上市 及 基 金 收 益 月 度跟 踪 — — 2025.06.02 3、中国 ...

证券代码：603233 证券简称：大参林 公告编号：2025-036 大参林医药集团股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持期间 2025 年 6 月 27 日～2025 年 9 月 26 日 拟减持股份来源 IPO 前取得，其他方式取得 拟减持原因 调整资产和融资结构，偿还个人债务，降低股票质押率 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延。 (一)相关股东是否有其他安排 □是 √否 (二)大股东及董监高此前对持股比例、持股数量、持股期限、减持方式、减持数 量、减持价格等是否作出承诺 √是 □否 （1）柯云峰、柯康保、柯金龙、柯舟、邹朝珠、梁小玲、王春婵、柯秀容 承诺：自发行人的股票上市之日起三十六个月内，不转让或者委托他人管理本人 直接和间接持有的发行人股份，也不由发行人回购该等股份。 （2）柯云峰、柯康 保、柯金龙同时承诺：在上述锁定期满后 12 个月内，减持公司股票数量不超过 其各自持有公司股份总数 ...

瑞康医药集团股份有限公司 上市公司名称:瑞康医药集团股份有限公司 股票简称：瑞康医药 股票代码：002589 股票上市地点:深圳证券交易所 信息披露义务人：荆州招商慧泽医药投资合伙企业（有限合伙） 住所或通讯地址：荆州经济技术开发区管委会1号楼招商中心一楼 股份变动性质：股份减少，持股比例降至5%以下 签署日期：2025年6月3日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》、 《上市公司收购管理办法》、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》及相关 的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报 告书已全面披露了信息披露义务人在瑞康医药集团股份有限公司以下简称"瑞康医 药"）中拥有权益的股份变动情况；截止本报告书签署之日，除本报告书披露的持股 信息外，上述信息披露义务人没有通过任何其他方式增加或减少其在瑞康医药拥有 权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的；除信息披露义务人外， 没有委托或授权任何其他人提供未在本报告书中列载的信息和 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-078 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 限制性股票登记日：2025 年 5 月 30 日 ? 授予登记人数：172 人 南京医药股份有限公司（以下简称"公司"）于 2025 年 5 月 30 日完成了 2025 年限制性股票激励计划首次授予登记工作，根据《上市公司股权激励管理办法》 等相关规则的规定，现将具体情况公告如下： 一、限制性股票授予情况 （一）基本情况 议审议通过了《关于向公司 2025 年限制性股票激励计划激励对象首次授予限制 性股票的议案》，相关议案已经公司董事会薪酬与绩效考核委员会 2025 年第三 次会议审议通过。公司监事会对本次激励计划首次授予激励对象名单进行了审核 并发表了核查意见。 公司本次激励计划限制性股票实际授予情况如下： 放弃认购公司向其授予的全部限制性股票共 4 万股，调整后实际授予数量由 （二）激励对象名单及实际授予情况 本激励计 ...

证券代码：600833 证券简称：第一医药 公告编号：临2025-023 上海第一医药股份有限公司 第十届董事会第三十三次（临时）会议 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十届董事会第三十三次（临时）会议于2025年5月25 日以邮件方式通知，于2025年5月30日以通讯方式召开。本次会议由董事长张海波先生召集并主持。本 次会议应参加表决董事为9名，委托表决0名，实际参加表决董事9名。会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于取消监事会后〈公司章程〉及配套制度修订的议案》 具体内容详见同日刊载于上海证券交易所网站www.sse.com.cn《上海第一医药股份有限公司关于取消监 事会并修订〈公司章程〉及配套制度的公告》（公告编号：临2025-025）。 表决结果：赞成9名，反对0 ...